|NCPE Assessment Process complete
|For the treatment of moderate to severe rheumatoid arthritis.
|Full submission received from Applicant
|NCPE assessment completed
|NCPE assessment outcome
|Reimbursement not Recommended.
The review group did not consider certolizumab cost-effective at the submitted price in September 2010.
The HSE has approved reimbursement following confidential price negotiations.